Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Prevalence of adverse events following T-cell redirecting therapies in patients with metastatic castration-resistant prostate cancer: a pooled analysis
Saved in:
| Published in: | The Oncologist |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
Similar Items: Prevalence of adverse events following T-cell redirecting therapies in patients with metastatic castration-resistant prostate cancer: a pooled analysis
- PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer
- Determinants of Adverse Events in Patients with Cancer Who Practiced Self-Medication: A Cross-Sectional Study in Southwestern Uganda
- Long-term complete response of metastatic adrenocortical carcinoma using streptozotocin-based therapy
- First-Line Tislelizumab Plus Chemotherapy for Advanced or Metastatic Squamous Non-Small Cell Lung Cancer: 4-Year Long-Term Follow-Up from RATIONALE-307
- Immune Cell Infiltration and Causal Relationships with Prostate Cancer: A Transcriptomic and Mendelian Randomization Study
- Metastatic neuroendocrine lesions in diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH): a narrative review and case series